ABT518

Known as: ABT-518 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2012
01220012012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
1. The potential of the matrix metalloproteinase (MMP) inhibitor ABT-518 to affect pre-adipocyte differentiation in vitro and… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2005
2005
Tetracyclines exhibit significant anti-inflammatory properties, inhibit matrix metalloproteinases (MMPs), and are protective in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay for the quantitative analysis of the novel anticancer drug… (More)
Is this relevant?
Review
2004
Review
2004
Matrix metalloproteinases (MMPs) have been implicated in several pathologies. At Abbott Laboratories, the matrix… (More)
Is this relevant?
2002
2002
A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP… (More)
Is this relevant?
2002
2002
Abstract Purpose. To investigate the pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase (MMP… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2001
2001
ABT-770 [(S)-N-[1-[[4'-trifluoromethoxy-[1,1'-biphenyl]-4-yl]oxy]methyl-2-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)ethyl]-N… (More)
Is this relevant?